Suppr超能文献

一种可报告疏水抑制性配体结合情况的荧光钙调蛋白。

A fluorescent calmodulin that reports the binding of hydrophobic inhibitory ligands.

作者信息

Johnson J D, Wittenauer L A

出版信息

Biochem J. 1983 May 1;211(2):473-9. doi: 10.1042/bj2110473.

Abstract

Ca2+ binding to calmodulin in the pCa range 5.5-7.0 exposes hydrophobic sites that bind hydrophobic inhibitory ligands, including calmodulin antagonists, some Ca2+-antagonists and calmodulin-binding proteins. The binding of these hydrophobic ligands to calmodulin can be followed by the approx. 80% fluorescence increase they produce in dansylated (5-dimethylaminonaphthalene-1-sulphonylated) calmodulin (CDRDANS). In the presence of Ca2+, calmodulin binds the calmodulin inhibitor, R24571, with an affinity of approx. 2-3 nM and hydrophobic ligands, including trifluoperazine (TFP), W-7 [N-(6-aminohexyl)-5-chloronaphthalene-1-sulphonamide], fendiline, felodipine and prenylamine, with affinities in the micromolar range. This binding is strongly Ca2+-dependent and Mg2+-independent. Calmodulin shows a reasonably high degree of specificity in its binding of these ligands over other ligands tested. CDRDANS, therefore, provides a convenient and simple means of monitoring the interaction of a variety of hydrophobic ligands with the Ca2+-dependent regulatory protein, calmodulin. CDRDANS binds to phospholipid vesicles made of (dimyristoyl)phosphatidylcholine (DMPC) or (dipalmitoyl)phosphatidylcholine (DPPC) and produces fluorescence increases only in the presence of Ca2+ and at temperatures above their gel-to-liquid crystalline phase transition. Although the fluorescence changes in CDRDANS accurately report phase transitions in these liposomes, its binding to these vesicles is weak. Calmodulin probably requires a high-affinity lipid-bound receptor protein for its high-affinity binding to natural membranes.

摘要

在pCa范围为5.5 - 7.0时,钙离子与钙调蛋白结合会暴露出疏水位点,这些位点可结合疏水抑制性配体,包括钙调蛋白拮抗剂、一些钙离子拮抗剂以及钙调蛋白结合蛋白。这些疏水配体与钙调蛋白的结合可通过它们在丹磺酰化(5 - 二甲基氨基萘 - 1 - 磺酰化)钙调蛋白(CDRDANS)中产生的约80%的荧光增强来追踪。在钙离子存在的情况下,钙调蛋白与钙调蛋白抑制剂R24571结合,亲和力约为2 - 3 nM,与疏水配体结合,包括三氟拉嗪(TFP)、W - 7 [N - (6 - 氨基己基) - 5 - 氯萘 - 1 - 磺酰胺]、芬地林、非洛地平和普尼拉明,亲和力在微摩尔范围内。这种结合强烈依赖钙离子且不依赖镁离子。与其他测试的配体相比,钙调蛋白在结合这些配体时表现出相当高的特异性。因此,CDRDANS提供了一种方便且简单的方法来监测多种疏水配体与钙离子依赖性调节蛋白钙调蛋白的相互作用。CDRDANS与由二肉豆蔻酰磷脂酰胆碱(DMPC)或二棕榈酰磷脂酰胆碱(DPPC)制成的磷脂囊泡结合,并且仅在钙离子存在且温度高于其凝胶 - 液晶相转变温度时才会产生荧光增强。尽管CDRDANS中的荧光变化准确地反映了这些脂质体中的相变,但其与这些囊泡的结合较弱。钙调蛋白可能需要一种高亲和力的脂质结合受体蛋白才能与天然膜进行高亲和力结合。

相似文献

2
Allosteric interactions among drug binding sites on calmodulin.钙调蛋白上药物结合位点之间的变构相互作用。
Biochem Biophys Res Commun. 1983 Apr 29;112(2):787-93. doi: 10.1016/0006-291x(83)91530-9.
8
The interaction of felodipine with calcium-binding proteins.非洛地平与钙结合蛋白的相互作用。
J Cardiovasc Pharmacol. 1987;10 Suppl 1:S53-9. doi: 10.1097/00005344-198710001-00010.

引用本文的文献

2
Effects of Phospholipase A2 Inhibitors on Bilayer Lipid Membranes.磷脂酶A2抑制剂对双层脂质膜的影响。
J Membr Biol. 2016 Jun;249(3):339-47. doi: 10.1007/s00232-016-9872-7. Epub 2016 Jan 13.
6
Inhibitors of membranous adenylyl cyclases.膜腺苷酸环化酶抑制剂。
Trends Pharmacol Sci. 2012 Feb;33(2):64-78. doi: 10.1016/j.tips.2011.10.006. Epub 2011 Nov 17.

本文引用的文献

9
Properties and functions of calmodulin.钙调蛋白的性质与功能。
Biochem Pharmacol. 1981 Jun 15;30(12):1395-405. doi: 10.1016/0006-2952(81)90358-0.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验